1. Home
  2. UP vs CLLS Comparison

UP vs CLLS Comparison

Compare UP & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wheels Up Experience Inc.

UP

Wheels Up Experience Inc.

HOLD

Current Price

$0.52

Market Cap

476.3M

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$3.24

Market Cap

384.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UP
CLLS
Founded
2013
1999
Country
United States
France
Employees
1866
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
476.3M
384.3M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
UP
CLLS
Price
$0.52
$3.24
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
1.8M
48.3K
Earning Date
04-30-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.49
$1.10
52 Week High
$3.50
$5.48

Technical Indicators

Market Signals
Indicator
UP
CLLS
Relative Strength Index (RSI) 41.12 42.08
Support Level $0.49 $3.32
Resistance Level $0.59 $3.83
Average True Range (ATR) 0.04 0.21
MACD 0.00 -0.02
Stochastic Oscillator 29.21 22.37

Price Performance

Historical Comparison
UP
CLLS

About UP Wheels Up Experience Inc.

Wheels Up Experience Inc is a provider of on-demand private aviation in the United States. It is pioneering data and technology-driven solutions that connect consumers to safety-vetted and verified private aircraft. It connects private flyers to aircraft, and one another, through an open platform that enables life's most important experiences. Its offering is delivered through a mix of programmatic and charter options that strategically utilize its owned and leased aircraft fleet and an "asset-light" charter model to deliver a greater range of global travel alternatives. The company operates in a single operating and reportable segment, private aviation services. Geographically the company generates the majority of its revenue from the United States.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: